Galantamine EP Impurity D

Development of a Novel High-Concentration Galantamine Formulation Suitable for Intranasal Delivery
Alexis kays leonard, anthony p. sileno, conor macevilly, charles a. foerder, steven c. quay, henry r. costantino
Journal of pharmaceutical sciences, vol. 94, no. 8, august 2005 pages 1736-1746
 
Methods for the analysis of galanthamine and its extraction from laboratory to industrial scale
Muhammad Nadeem Akramab Robert Verpoortea Barbora Pomahačová
South African Journal of Botany Volume 136, January 2021, Pages 51-64
 
Determination of galantamine hydrobromide in bulk drug and pharmaceutical dosage form by spectrofluorimetry
Amit V. Patel, Vishal J. Patel, Avani V. Patel, Jayant B. Dave, Chhaganbhai N. Patel
J Pharm Bioallied Sci. 2013 Oct-Dec; 5(4): 314–317
 
Quantitative analysis of drugs in biological matrices by HPLC hyphenated to fluorescence detection
Emmanuelle Lipka & Claude Vaccher
Bioanalysis (2015) 7(6), 743–762

Galantamine EP Impurity D is chemically (4aS,8aS)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepine. It is also known as Anhydro Galantamine. Galantamine EP Impurity D is supplied with detailed characterization data compliant with regulatory guideline. Galantamine EP Impurity D can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Galantamine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.